NeuroPace (NPCE) Stock Forecast & Price Target

$7.96

-0.16 (-1.97%)

(As of 07/26/2024 ET)

NeuroPace - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for NeuroPace in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for NPCE.

Consensus Price Target

$14.83
86.35% Upside

High Forecast	$22.00
Average Forecast	$14.83
Low Forecast	$8.00

According to the 7 analysts' twelve-month price targets for NeuroPace, the average price target is $14.83. The highest price target for NPCE is $22.00, while the lowest price target for NPCE is $8.00. The average price target represents a forecasted upside of 86.35% from the current price of $7.96.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$14.83	$15.67	$15.67	$7.25
Forecasted Upside	86.35% Upside	39.74% Upside	32.64% Upside	64.96% Upside

Get NeuroPace Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.

Ad WealthPress

This TSLA short trade is on a nine win hot streak

Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.

But I can promise that you’ll see all the details for yourself here.

NPCE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NPCE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

NeuroPace Stock vs. The Competition

Type	NeuroPace	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	86.35% Upside	3,121.51% Upside	9.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/15/2024	Morgan Stanley 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$9.50 ➝ $8.00	+1.14%
5/9/2024	Cantor Fitzgerald 3 of 5 stars	R. Osborn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$18.00	+94.81%
3/14/2024	Wells Fargo & Company 3 of 5 stars		Upgrade	Equal Weight ➝ Overweight	$16.00 ➝ $20.00	+49.48%
1/30/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/30/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$22.00	+49.15%
12/27/2023	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$12.00	+21.95%
11/7/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$6.00 ➝ $9.00	+24.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:18 AM ET.

NPCE Forecast - Frequently Asked Questions

What is NeuroPace's forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for NeuroPace is $14.83, with a high forecast of $22.00 and a low forecast of $8.00.
Should I buy or sell NeuroPace stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
Does NeuroPace's stock price have much upside?: According to analysts, NeuroPace's stock has a predicted upside of 42.77% based on their 12-month stock forecasts.
What analysts cover NeuroPace?: NeuroPace has been rated by research analysts at Cantor Fitzgerald, and Morgan Stanley in the past 90 days.
Do Wall Street analysts like NeuroPace more than its competitors?: Analysts like NeuroPace more than other "medical" companies. The consensus rating score for NeuroPace is 2.86 while the average consensus rating score for "medical" companies is 2.72. Learn more on how NPCE compares to other companies.